Approaches to prevent bleeding associated with anticoagulants: current status and recent developments (Q39456319)

12 September 2017

title

Approaches to prevent bleeding associated with anticoagulants: current status and recent developments (English)

1 reference

Jayachandran N Kizhakkedathu

12 September 2017

1 reference

series ordinal

3

object named as

Jayachandran N Kizhakkedathu

1 reference

12 September 2017

author name string

Manu Thomas Kalathottukaren

series ordinal

1

1 reference

12 September 2017

Charles A Haynes

series ordinal

2

1 reference

12 September 2017

publication date

24 July 2017

1 reference

Drug delivery and translational research

12 September 2017

published in

1 reference

New fundamentals in hemostasis

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Thrombosis: a major contributor to global disease burden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Triggers, targets and treatments for thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Management of venous thromboembolism: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Global Burden of Thrombosis: Epidemiologic Aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Arterial thrombosis--insidious, unpredictable and deadly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Extracellular DNA traps promote thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Oral direct factor Xa inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Idarucizumab for Dabigatran Reversal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Heparin and heparan sulfate: analyzing structure and microheterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Molecular mechanisms of antithrombin-heparin regulation of blood clotting proteinases. A paradigm for understanding proteinase regulation by serpin family protein proteinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

The anticoagulant and antithrombotic mechanisms of heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Structure of a serpin-protease complex shows inhibition by deformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Conformational activation of antithrombin by heparin involves an altered exosite interaction with protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Molecular basis of factor IXa recognition by heparin-activated antithrombin revealed by a 1.7-A structure of the ternary complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

On the specificity of heparin/heparan sulfate binding to proteins. Anion-binding sites on antithrombin and thrombin are fundamentally different

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Pharmacology of Heparin and Related Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

The heparin binding properties of heparin cofactor II suggest an antithrombin-like activation mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Heparin/heparan sulphate-based drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Post-discharge compliance to venous thromboembolism prophylaxis in high-risk orthopaedic surgery: results from the ETHOS registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Apixaban versus enoxaparin for thromboprophylaxis after hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Oral apixaban for the treatment of acute venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Edoxaban versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: findings from the ORTHO-TEP registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Components and assembly of the factor X activating complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

The pharmacology and therapeutic use of dabigatran etexilate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Dabigatran: Review of Pharmacology and Management of Bleeding Complications of This Novel Oral Anticoagulant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Dabigatran versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Dabigatran versus warfarin in the treatment of acute venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Adverse drug reaction deaths reported in United States vital statistics, 1999-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Heparin sensing and binding - taking supramolecular chemistry towards clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Allergy to protamine sulfate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Alteration of blood clotting and lung damage by protamine are avoided using the heparin and polyphosphate inhibitor UHRA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

A [ 18RGD] protamine variant for nontoxic and effective reversal of conventional heparin and low-molecular-weight heparin anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Low molecular weight protamine: a potent but nontoxic antagonist to heparin/low molecular weight protamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

PEG-modified protamine with improved pharmacological/pharmaceutical properties as a potential protamine substitute: synthesis and in vitro evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Recombinant platelet factor 4 for heparin neutralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Heparinase I (neutralase) reversal of systemic anticoagulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Nonclinical Safety Assessment of PER977: A Small Molecule Reversal Agent for New Oral Anticoagulants and Heparins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Preclinical and Clinical Data for Factor Xa and "Universal" Reversal Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Affinity-based design of a synthetic universal reversal agent for heparin anticoagulants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Chitosan derivatives as novel potential heparin reversal agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

The Toxicokinetic Profile of Dex40-GTMAC3-a Novel Polysaccharide Candidate for Reversal of Unfractionated Heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Effect of PEG-PDMAEMA Block Copolymer Architecture on Polyelectrolyte Complex Formation with Heparin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

A chemically-modified inactive antithrombin as a potent antagonist of fondaparinux and heparin anticoagulant activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Idarucizumab: The Antidote for Reversal of Dabigatran

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

A specific antidote for dabigatran: functional and structural characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Factor XII inhibition reduces thrombus formation in a primate thrombosis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Factor XI and contact activation as targets for antithrombotic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Factor XIIa inhibition by Infestin-4: in vitro mode of action and in vivo antithrombotic benefit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Nontoxic polyphosphate inhibitors reduce thrombosis while sparing hemostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13346-017-0413-4

Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives

21 January 2018

1 reference

12 December 2020

The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study

1 reference

12 December 2020

Protamine: a review of its toxicity

1 reference

12 December 2020

Dermatan sulfate is the predominant antithrombotic glycosaminoglycan in vessel walls: implications for a possible physiological function of heparin cofactor II

1 reference

12 December 2020

Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies

1 reference

12 December 2020

Risk factors for venous and arterial thrombosis

1 reference

12 December 2020

Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation

1 reference

12 December 2020

Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban

1 reference

12 December 2020

Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality

1 reference

12 December 2020

Four-factor prothrombin complex concentrate for urgent reversal of vitamin K antagonists in patients with major bleeding

1 reference

12 December 2020

Bleeding complications associated with cardiopulmonary bypass.

1 reference

12 December 2020

Use of PER977 to reverse the anticoagulant effect of edoxaban

1 reference

12 December 2020

Randomized trial of recombinant platelet factor 4 versus protamine for the reversal of heparin anticoagulation in humans

1 reference

12 December 2020

Cationic derivatives of dextran and hydroxypropylcellulose as novel potential heparin antagonists

1 reference

12 December 2020

Heparin cofactor II inhibits arterial thrombosis after endothelial injury

1 reference

12 December 2020

Efficacy and safety of heparinase I versus protamine in patients undergoing coronary artery bypass grafting with and without cardiopulmonary bypass

1 reference

12 December 2020

Protamine-induced immune thrombocytopenia.

1 reference

12 December 2020

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

1 reference

12 December 2020

10.1007/S13346-017-0413-4

Identifiers

DOI

1 reference

12 September 2017

1 reference